8-K Announcements
6Material company update
Feb 17, 2026·SEC
Material company update
Jan 22, 2026·SEC
Material company update
Dec 29, 2025·SEC
Ekso Bionics Holdings, Inc.(EKSO)Earnings, Financials & Key Ratios
EKSO•NASDAQ
$15.90
Price updated Jul 7, 2026
AboutEkso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.Show more
- Revenue$13M-28.6%
- EBITDA-$12M-32.8%
- Net Income-$12M-3.2%
- EPS (Diluted)-4.91-776.8%
- Gross Margin53.48%+0.8%
- EBITDA Margin-91.83%-85.9%
- Operating Margin-104.12%-78.4%
- Net Margin-91.37%-44.6%
- ROE-107.62%-20.2%
EKSO Price & Volume
Ekso Bionics Holdings, Inc. (EKSO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Signals Existential Liquidity Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and solvency
Key Thesis Takeaways
- Ekso Bionics faces a critical inflection point as its core medical device business struggles with a 36.6% year-over-year revenue decline in 2026Q1 and a deeply entrenched operating loss structure.
- The company's inability to scale revenue against high SG&A expenses, which consistently dwarf gross profit, suggests a fundamental failure in its current commercialization strategy.
- Investors should remain cautious as the firm's accumulated deficit of $269.3 million and dwindling cash reserves of $1.2 million as of 2025Q4 indicate a high probability of continued dilution or insolvency risk.
Verdict Logic
the company's inability to generate positive free cash flow, combined with a 36.6% revenue contraction in 2026Q1, suggests an imminent risk to its going-concern status.
EKSO Growth Metrics
Ekso Bionics Holdings, Inc. (EKSO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.98%
5 Years7.58%
3 Years-0.29%
TTM-34.08%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-45.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1022.92%
Return on Capital
10 Years-94.33%
5 Years-57.38%
3 Years-65.7%
Last Year-87.13%
EKSO Recent Earnings
Ekso Bionics Holdings, Inc. (EKSO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 5/12 qtrs (42%)
Q1 2026Latest
Feb 23, 2026Metric
Actual
Est
EPS
$1.56-1850.0%
$0.08
Rev
$3M-37.5%
$5M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$0.54+45.5%
$0.99
Rev
$4M-15.9%
$5M
Q3 2025
Jul 28, 2025Metric
Actual
Est
EPS
$1.24-3.3%
$1.20
Rev
$2M-50.4%
$4M
Q2 2025
May 5, 2025Metric
Actual
Est
EPS
$1.80-9.1%
$1.65
Rev
$3M-38.7%
$6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 23, 2026 | $1.56vs $0.08-1850.0% | $3Mvs $5M-37.5% |
| Q4 2025 | Oct 28, 2025 | $0.54vs $0.99+45.5% | $4Mvs $5M-15.9% |
| Q3 2025 | Jul 28, 2025 | $1.24vs $1.20-3.3% | $2Mvs $4M-50.4% |
| Q2 2025 | May 5, 2025 | $1.80vs $1.65-9.1% | $3Mvs $6M-38.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Ekso Bionics Holdings, Inc. (EKSO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.90 | $38.57M | -3.24 | -28.6% | -91.37% | -107.62% | 0.59% | |
| $0.05 | $1.72M | -0.01 | -23.44% | -38.16% | — | — | |
| $408.85 | $20.64B | -139.54 | 36.01% | -10.79% | -6.11% | — | |
| $5.19 | $1.91B | -1.78 | 1227.6% | -19019.44% | -366.21% | — | |
| $1.16 | $44.82M | -3.14 | 25.73% | -36.69% | -114.87% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — |
Compare EKSO vs Peers
Ekso Bionics Holdings, Inc. (EKSO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EKSO SEC Filings & Documents
Ekso Bionics Holdings, Inc. (EKSO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when EKSO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EKSO Frequently Asked Questions
Ekso Bionics Holdings, Inc. (EKSO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Ekso Bionics Holdings, Inc.'s revenue?
Ekso Bionics Holdings, Inc. (EKSO) reported $11.6M in revenue for fiscal year 2025. This represents a 250% increase from $3.3M in 2013.
How fast is Ekso Bionics Holdings, Inc. growing?
Ekso Bionics Holdings, Inc. (EKSO) saw revenue decline by 28.6% over the past year.
Is EKSO profitable?
Ekso Bionics Holdings, Inc. (EKSO) reported a net loss of $15.7M for fiscal year 2025.
Dividend & Returns
Does EKSO pay dividends?
Yes, Ekso Bionics Holdings, Inc. (EKSO) pays a dividend with a yield of 0.59%. This makes it attractive for income-focused investors.
What is EKSO's return on equity?
Ekso Bionics Holdings, Inc. (EKSO) has a return on equity (ROE) of -107.6%. Negative ROE indicates the company is unprofitable.
What is Ekso Bionics Holdings, Inc.'s free cash flow?
Ekso Bionics Holdings, Inc. (EKSO) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.